Medtronic (MDT)

The device, known as the Layer 7 Cortical Interface, is a thin, flexible microelectrode array designed to record and stimulate neural activity without penetrating brain tissue.

U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip export restrictions to China.

Dexcom stock surged Thursday after the FDA cleared its newest diabetes device for an extended 15-day wear time.

In a welcome move, Medtronic stock saw its Relative Strength Rating improve to 73 on Tuesday, up form 67 a day earlier.

The medical device maker has been a huge winner for its long-term shareholders.

Analyzing MEDTRONIC PLC (NYSE:MDT)'s Dividend Potential.

Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs.

China is stepping up efforts to reassure U.S. corporate giants like Apple, Pfizer, and Mastercard of its economic potential, with Vice Premier He Lifeng promising a better business environment amid rising U.S. tariff pressures and slowing foreign investment.

Balancing Dividends and Fundamentals: The Case of MEDTRONIC PLC (NYSE:MDT).

MEDTRONIC PLC (NYSE:MDT) Reveals Intriguing Technical Aspects. Indications Suggest NYSE:MDT Could Be on the Verge of a Breakout. Here's What You Need to Know.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.

Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news

Medtronic is on track to complete a market reversal later this year as investments in technology and innovation begin to pay off.